Compare NTZ & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTZ | TPST |
|---|---|---|
| Founded | 1959 | 2011 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 15.6M |
| IPO Year | 1998 | 2012 |
| Metric | NTZ | TPST |
|---|---|---|
| Price | $1.55 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 3.2K | ★ 98.1K |
| Earning Date | 04-13-2023 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.50 | $0.93 |
| 52 Week High | $3.95 | $12.22 |
| Indicator | NTZ | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 32.51 | 37.00 |
| Support Level | $1.50 | N/A |
| Resistance Level | $2.00 | $2.48 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 12.00 | 34.93 |
Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture, sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private Label, and Natuzzi Editions. The Group operates in two operating segments, the Natuzzi brand and Private label. The Natuzzi brand segment includes net sales from the Natuzzi Italia, Natuzzi Editions, and Divani&Divani by Natuzzi product lines. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.